FDA asks Crohn’s disease and Arthiritis drugs asked to be more specific on warnings

Four popular drugs for Crohn’s disease and arthritis were asked to incorporate additional black box warnings on their labels on Thursday by the Federal regulators. According to them, users have to be warned on the possible risk of serious fungal infections.
UCB SA’s Cimzia, Johnson & Johnson’s Remicade, Amgen Inc. and Wyeth’s Enbrel and Abbot laboratories’ Humira were the drugs which were asked to incorporate strong black box warnings by the US Food and Drug Administration.

Following granting of extra powers to the FDA by Congress the previous year, the agency is demanding issue of warnings due to their concern over whether serious infections in patients who are on these drugs are being properly diagnosed by the health care professionals and doctors.

According to Jeffrey Siegel, chief of arthritis products regulation division of FDA, all these companies are being co operative in this regard. Demand for issue of warnings follow reporting of at least 45 cases of death due to histoplasmosis in patients ho were taking these drugs, most of them from the Mississippi river and Ohio river valleys.

Histoplasmosis is a flu like respiratory disease. According to FDA, these drugs which are known as TNF blockers reduce the immunity in patients making them susceptible to fungal infections.
Siegel went on to explain that histoplasmosis is a condition which is difficult to diagnose as it is similar to certain other conditions. The symptoms for this disease include constant fever, cough and fatigue.

Though warning labels for infections are already present, FDA wants more specific warnings detailing the risk of the possibility of histoplasmosis.

Online Top Stories Legal News Distribution - Business News Magazine